Listed by the USPTO as WHITE, DAWANNA SHAR-DAY
Tech Center 1600 • Art Units: 1627 1629
This examiner grants 63% of resolved cases
WHITE, DAWANNA SHAR-DAY is assigned to Tech Center 1600 and Art Unit 1627. Her profile records 130 resolved cases, a 63.1% allowance rate, a 21.1% interview lift, and a median of 1266 days to allowance.
The data supports a prosecution approach that combines substantive claim presentation with examiner engagement. The positive interview lift indicates that interviews may improve outcomes in appropriate cases, although the median timeline remains extended. The listed companies are BioTheryX Inc., Fujifilm Holdings Corporation, and Novartis AG. The listed firms are Jones Day, Juniv LLP, and McCarter & English, LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18892564 | COMPOUND AND PRODUCTION METHOD THEREOF, POLYMERIZABLE COMPOSITION, RESIN COMPOSITION, POLYMER, CURED SUBSTANCE, AND LAMINATE | Non-Final OA | FUJIFILM Corporation |
| 18960021 | NEW CRYSTALLINE FORMS OF SALT OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE -6-CARBOXYLIC ACID DIMETHYLAMIDE | Non-Final OA | Novartis AG |
| 18951962 | GPR88-RECEPTOR-AGONIST | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18834350 | IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18101772 | COMPOUNDS AND METHODS FOR TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18755002 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Non-Final OA | VANDERBILT UNIVERSITY |
| 18865738 | CRYSTALLINE FORMS OF PICOLINAMIDE FUNGICIDE COMPOUND | Non-Final OA | CORTEVA AGRISCIENCE LLC |
| 18548657 | SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18973967 | METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES | Non-Final OA | Duke University |
| 18857231 | SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18840040 | METHODS OF TREATING, AMELIORATING, OR PREVENTING HEART FAILURE, AND METHODS OF PROMOTING HEART MUSCLE GROWTH | Non-Final OA | Yale University |
| 18034965 | METHODS OF TREATING TUMORS AND CANCERS HAVING DYSREGULATED WNT SIGNALING PATHWAYS | Final Rejection | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18852579 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | Non-Final OA | Praxis Precision Medicines, Inc. |
| 18549249 | TREATING CANCER IN PATIENT HAVING CO-OCCURRING GENETIC ALTERATION IN FGFR2 AND A CANCER DRIVER GENE | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18910811 | PLATINUM COMPLEXES AND DEVICES | Non-Final OA | Universal Display Corporation |
| 18288734 | METHODS FOR TREATING AND MONITORING PARKINSON'S DISEASE | Final Rejection | Denali Therapeutics Inc. |
| 18833879 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. |
| 18713561 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Non-Final OA | REMIX THERAPEUTICS INC. |
| 18072314 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Non-Final OA | Twelve Therapeutics, Inc. |
| 18550488 | SARS-CoV-2 inhibitors - artificial compounds | Final Rejection | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.1% of resolved applications examined by Dawanna Shar-Day White were allowed (130 resolved cases), compared with 35.4% across Art Unit 1627 over the last five years.
This examiner's interview lift is +21.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Dawanna Shar-Day White took 1,266 days on average from filing to allowance.
Dawanna Shar-Day White examines applications in Art Unit 1627 in Tech Center 1600 (Biotechnology & Pharmaceuticals).